For a wound abscess caused by Enterobacter that was previously resistant to cephalosporins and is currently being treated with vancomycin and meropenem, what is the appropriate antibiotic regimen and should vancomycin be continued?

Discontinue Vancomycin Immediately for Enterobacter Wound Abscess

Vancomycin should be stopped immediately—it has no activity against Enterobacter species and provides no benefit for this infection. Meropenem alone is the appropriate antibiotic for a wound abscess caused by cephalosporin-resistant Enterobacter.

Why Vancomycin Must Be Discontinued

Vancomycin is exclusively active against Gram-positive organisms, particularly methicillin-resistant Staphylococcus aureus (MRSA) and enterococci 1. Enterobacter is a Gram-negative bacillus—vancomycin has zero activity against it. The FDA labeling confirms vancomycin is indicated only for staphylococcal and enterococcal infections 1. Continuing vancomycin exposes the patient to unnecessary nephrotoxicity risk without any therapeutic benefit.

Appropriate Antibiotic Regimen

Meropenem monotherapy is the correct treatment for cephalosporin-resistant Enterobacter wound abscess. Here's the evidence-based approach:

For Enterobacter (AmpC-producing organism):

• Meropenem 1-2g IV every 8 hours is the drug of choice for severe infections caused by third-generation cephalosporin-resistant Enterobacterales 2
• Cefepime is an alternative option, but given the previous cephalosporin resistance and severity requiring meropenem initially, continuing meropenem is appropriate 3, 4
• Duration: Continue until surgical debridement is no longer necessary, clinical improvement is achieved, and patient has been afebrile for 48-72 hours 5

Source Control is Critical

The IDSA guidelines emphasize that surgical drainage and debridement are essential for wound abscesses 5. Antibiotics are adjunctive therapy—adequate source control is the primary treatment. Ensure:

• Complete drainage of purulent material
• Debridement of necrotic tissue
• Repeat imaging if fever persists to identify undrained collections 5

Key Clinical Pitfalls to Avoid

1. Don't continue vancomycin "just in case": This is a common error. If cultures show pure Enterobacter growth with no Gram-positive organisms, vancomycin serves no purpose and increases toxicity risk

2. Don't use third-generation cephalosporins: The organism was previously resistant to cephalosporins, likely due to AmpC β-lactamase production. Third-generation cephalosporins can induce AmpC overexpression leading to treatment failure 3

3. Don't use piperacillin-tazobactam for severe Enterobacter infections: While sometimes used for low-risk infections, it's not recommended for severe wound abscesses due to AmpC resistance mechanisms 4

4. Monitor for carbapenem resistance: If the patient fails to improve on meropenem, consider carbapenem-resistant Enterobacterales (CRE). In that scenario, newer agents like meropenem-vaborbactam or ceftazidime-avibactam would be needed 2, 6

Simplified Treatment Algorithm

Enterobacter wound abscess + previous cephalosporin resistance
↓
1. SURGICAL DRAINAGE (primary treatment)
↓
2. MEROPENEM monotherapy (1-2g IV q8h)
↓
3. STOP vancomycin (no Gram-positive activity needed)
↓
4. Continue until: afebrile 48-72h + clinical improvement + no further debridement needed
↓
5. If failure → check for CRE → consider meropenem-vaborbactam or ceftazidime-avibactam

The bottom line: Your current regimen should be simplified to meropenem alone, with vancomycin discontinued immediately. The combination was never indicated for Enterobacter, and continuing unnecessary antibiotics violates antimicrobial stewardship principles while exposing the patient to avoidable toxicity 2.